GalleriTM
multi-cancer early
detection test
The benefits of multi-cancer detection
The Galleri test detects more than 50 types of cancer through a simple blood draw.1
Early cancer detection
Early detection can help improve treatment outcomes and survival. The Galleri test detects many cancers that are not commonly screened for today, to allow for earlier treatment.1,2
Testing with ease
The Galleri test can be incorporated into a routine healthcare visit through a simple blood draw.
Actionable results
If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help your healthcare provider guide your next steps.
How it works
All cells in your body release DNA into the bloodstream, but DNA from cancer cells is different from the DNA of healthy cells.3
The Galleri test looks at the DNA in your blood to determine if any of it may have come from cancer cells, and the results can point to where in the body the cancer is coming from.
Who can benefit
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends.
Rate of new cancers by age group3
Talk to your healthcare provider about your risk for cancer, and whether the Galleri test is right for you.
Important safety information
The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests. Results should be interpreted by a healthcare provider. A “Cancer Signal Not Detected” result does not rule out cancer. A “Cancer Signal Detected” result requires confirmatory diagnostic evaluation (e.g. imaging), and if cancer is not confirmed, it may not be present, may not be detectable by diagnostic follow-up testing or may be located in a different part of the body. False-positive and false-negative test results do occur. Rx only.
Laboratory / test information
The GRAIL laboratory is CLIA-certified and CAP-accredited. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by FDA. The GRAIL laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is for clinical purposes.
Sign up for more information about the Galleri test
- Klein E, et al. Clinical validation of a targeted methylation·based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
- The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
- Bronkhorst AJ, et al. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. https://www.sciencedirect.com/science/article/pii/S221475351830024X
- Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999−2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2020.